Literature DB >> 22168912

Vascular endothelial growth factor in the ischemic retina and its regulation by somatostatin.

Davide Cervia1, Elisabetta Catalani, Massimo Dal Monte, Giovanni Casini.   

Abstract

In a retinal ischemic ex vivo model, we have reported protective effects of somatostatin (SRIF) receptor 2 (sst(2) ). As an ischemic condition not only causes cell death but also induces a vascular response, we asked whether vascular endothelial growth factor (VEGF) is altered in this model and whether its expression, release or localization are affected by sst(2) activation. Ex vivo retinas of wild-type (WT) and sst(1) KO mice (which over-express sst(2) ) were incubated in ischemic conditions with SRIF, octreotide (OCT) or a VEGF trap. Ischemia in WT retinas caused increase of VEGF release and decrease of VEGF mRNA. Both effects were counteracted by SRIF or OCT. VEGF immunoreactivity was in retinal neurons and scarcely in vessels. Ischemia caused a significant shift of VEGF immunoreactivity from neurons to vessels. The increase of vascular VEGF was reduced in sst(1) KO retinas and in WT retinas treated with SRIF or OCT. VEGF trap also limited this increase, demonstrating that vascular VEGF was of extracellular origin. Together, the data show a VEGF response to ischemia, in which VEGF released by damaged neurons reaches the retinal capillaries. The activation of sst(2) protects neurons from ischemic damage, thereby limiting VEGF release and the VEGF response.
© 2011 The Authors. Journal of Neurochemistry © 2011 International Society for Neurochemistry.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22168912     DOI: 10.1111/j.1471-4159.2011.07622.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  24 in total

1.  Effects of long-acting somatostatin analogues on redox systems in rat lens in experimental diabetes.

Authors:  Sirilaksana Kunjara; A Leslie Greenbaum; Milena Sochor; Allan Flyvbjerg; Henning Grønbaek; Patricia McLean
Journal:  Int J Exp Pathol       Date:  2014-03-06       Impact factor: 1.925

Review 2.  Neurovascular cross talk in diabetic retinopathy: Pathophysiological roles and therapeutic implications.

Authors:  Elizabeth P Moran; Zhongxiao Wang; Jing Chen; Przemyslaw Sapieha; Lois E H Smith; Jian-Xing Ma
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-07-29       Impact factor: 4.733

3.  Occludin downregulation in high glucose is regulated by SSTR2 via the VEGF/NRP1/Akt signaling pathway in RF/6A cells.

Authors:  Mengling Li; Shuaiwei Wang; Songjiang Wang; Lei Zhang; Dongdong Wu; Ruisheng Yang; Ailing Ji; Yanzhang Li; Jun Wang
Journal:  Exp Ther Med       Date:  2017-06-22       Impact factor: 2.447

Review 4.  Neuropeptides and diabetic retinopathy.

Authors:  Robert Gábriel
Journal:  Br J Clin Pharmacol       Date:  2013-05       Impact factor: 4.335

Review 5.  Somatostatin and diabetic retinopathy: current concepts and new therapeutic perspectives.

Authors:  Cristina Hernández; Olga Simó-Servat; Rafael Simó
Journal:  Endocrine       Date:  2014-03-14       Impact factor: 3.633

Review 6.  The progress of prophylactic treatment in retinopathy of prematurity.

Authors:  Hong-Bing Zhang; Xiao-Dong Wang; Kun Xu; Xiao-Gang Li
Journal:  Int J Ophthalmol       Date:  2018-05-18       Impact factor: 1.779

7.  NADPH oxidase 4-derived H2O2 promotes aberrant retinal neovascularization via activation of VEGF receptor 2 pathway in oxygen-induced retinopathy.

Authors:  Jingming Li; Joshua J Wang; Sarah X Zhang
Journal:  J Diabetes Res       Date:  2015-03-18       Impact factor: 4.011

8.  Hormones and immunity in cancer: are thyroid hormones endocrine players in the microglia/glioma cross-talk?

Authors:  Cristiana Perrotta; Clara De Palma; Emilio Clementi; Davide Cervia
Journal:  Front Cell Neurosci       Date:  2015-06-23       Impact factor: 5.505

9.  The Neuropeptide Systems and their Potential Role in the Treatment of Mammalian Retinal Ischemia: A Developing Story.

Authors:  D Cervia; G Casini
Journal:  Curr Neuropharmacol       Date:  2013-01       Impact factor: 7.363

10.  Topical administration of somatostatin prevents retinal neurodegeneration in experimental diabetes.

Authors:  Cristina Hernández; Marta García-Ramírez; Lidia Corraliza; Jimena Fernández-Carneado; Josep Farrera-Sinfreu; Berta Ponsati; Agueda González-Rodríguez; Angela M Valverde; Rafael Simó
Journal:  Diabetes       Date:  2013-03-08       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.